In bygone centuries, medicine consisted of bloodletting and leeches. Cures were simple and inexpensive, if petrifying. But with the modern development of pharmaceuticals, and the human predilection for consuming a pill over having a malfunctioning body part excised by a moonlighting barber, the drug industry has become one of the world’s largest and most profitable. That’s something Pfizer, Inc. (PFE) shareholders have well understood for decades.

Since 2009 Pfizer has been among the 40 stocks that comprise the Dow Jones Industrial Average. Its subsidiaries include several formerly stand-alone pharmaceutical companies enormous in their own right, among them Parke-Davis, Wyeth and Searle. Pfizer's 2009 Wyeth acquisition alone represented the largest corporate takeover in years, costing it $68 billion, one-third of that money financed. That banks were willing to lend $23 billion at a time when money was notoriously tight speaks to Pfizer’s consistent profitability. (For related reading, see: How Johnson & Johnson Became a Household Name.)

Blue Chip Before Blue Pills

To the unassuming public, one drug company is largely indistinguishable from the next. They develop, they test, they patent, they sell, they get fined by the U.S. Food and Drug Administration. But to observant investors, drug companies differ greatly. A roster of effective, heavily-prescribed, high-margin medications can turn a manufacturer from a struggling also-ran to the bluest of blue chips. And Pfizer’s line includes some of the most (financially) potent drugs in existence.

Pfizer’s history goes back to 1849, its first few chapters including steady growth and the development of crucial antibiotics that saved the lives of countless infected Allied soldiers during World War II. But the company’s story reached a climax with the 1998 debut of sildenafil, a drug originally intended to combat the effects of pulmonary hypertension. You might know it by its alternate application, and/or by its trademarked name: Viagra.

Dominant Market Share

Chemically induced tumescence wasn’t always a staple of romantic life. Viagra represented so groundbreaking a development that within a year of its release, it enjoyed close to a 100% share of a rising and ever more virile market. While several competitors – notably Bayer/GlaxoSmithKline plc’s (GSK) Levitra and Eli Lilly and Co.’s (LLY) Cialis – have since cut into Pfizer’s profits, Viagra still accounts for almost half of worldwide erectile dysfunction prescriptions. (For related reading, see: Evaluating Pharmaceutical Companies.)

The $2 billion the company makes annually on Viagra represents only about 4% of Pfizer’s revenue, but the margins on Viagra are something to behold. The company understandably doesn’t release figures on how much it costs to create each marginal Viagra pill, but we can deduce its cost indirectly. Pfizer’s patent for Viagra expired in Europe in 2013, and the predicted rush of generics to market has happened in earnest. Given that Viagra knockoffs now sell for barely $1 a pill in the United Kingdom, the cost of producing them must be less. Viagra retails for about $10-15 in the U.S., where its patent doesn’t expire until 2017. You can thus figure the profit margins out yourself; the math, at least, is not hard.

But Not Just Viagra

The success of the world’s favorite impotence treatment isn’t even Pfizer’s most notable success. As remarkably as Viagra sales thrust upward after their late-‘90s release, the drug remains only Pfizer’s third-biggest seller in the United States and Canada. The company’s flagship drug on its home continent, at least for now, is Lyrica – used to treat fibromyalgia, epilepsy, and other diseases that cause patients to convulse.

Pfizer sold $625 million worth of Lyrica in the most recent quarter for which figures are available, fully twice the revenue generated by Viagra. Despite Lyrica’s intended specialized use – for the treatment of a disease that often manifests itself in violent and debilitating seizures – in practice Lyrica is mostly prescribed for patients who suffer from anxiety. Name-brand Lyrica sells for around $2-3 a pill, a price Pfizer will enjoy until generic pregabalin appears in the U.S. market in 2018.

A Pill For What Ails You

Not far behind Lyrica on the list of Pfizer’s top sellers is Celebrex, an anti-inflammatory medication that Pfizer recommends for the treatment of arthritis. The company sells well over $2 billion worth of Celebrex in North America annually, a number that’s remained consistent for several years. Depending on strength, Celebrex capsules retail for around $1.50 or $3 per capsule. (For related reading, see: Pharmaceutical Phenoms: America's best-Selling Medicines.)

The remaining largest contributors to Pfizer’s revenue total (which routinely stands at over $50 billion annually) include Lipitor (a statin that lowers blood cholesterol), Zoloft (an antidepressant), and the noted over-the-counter pain reliever Advil. A special case is Prevnar 13, a vaccine intended to prevent pneumonia in adults and which technically counts as Pfizer’s second-most lucrative offering after Lyrica, with worldwide sales approaching $4 billion last year.

As to why Advil isn’t higher up the list of Pfizer’s biggest sellers, as an over-the-counter medication Advil falls under the purview of the company’s consumer healthcare division. That’s where you’ll also find such common household medicine cabinet staples as Dimetapp, Robitussin, ChapStick and Centrum. Yet despite those products’ ubiquity, consumer healthcare operations are responsible for a mere 7% of Pfizer’s income.

The Bottom Line

The fact is undeniable – pharmaceuticals, the brainchildren of untold man-years and billions of dollars of research and development, represent the overwhelming share of Pfizer’s business. And will continue to indefinitely. (For related reading, see: Pharmaceutical vs. Biotech Investing: Is It Worth The Risk.)

Related Articles
  1. Stock Analysis

    How Warren Buffett made Berkshire Hathaway a World-beater

    It would almost be easier to list the industry sectors in which Omaha-based Berkshire Hathaway Inc. (NYSE:BRK.A) doesn’t turn gargantuan profits.
  2. Mutual Funds & ETFs

    ETF Analysis: Direxion Daily Healthcare Bull 3X

    Learn about the Direxion Daily Healthcare Bull. This is a leveraged ETF that tracks the health care sector, which is a leader in this bull market.
  3. Mutual Funds & ETFs

    ETF Analysis: Vanguard Intermediate-Term Corp Bd

    Learn about the Vanguard Intermediate-Term Corporate Bond ETF, and explore detailed analysis of the fund's characteristics, risks and historical statistics.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares National AMT-Free Muni Bond

    Take an in-depth look at the iShares National AMT-Free Municipal Bond ETF, a highly diverse and very popular muni bond fund.
  5. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  6. Investing News

    Fund Firm Jolts: Pimco's Isn't The First Or Worst

    When you business is built on prudence and trust, a lot can go wrong to cost you tons of clients and assets. Here are a few examples.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares JPMorgan USD Emerg Markets Bond

    Learn about the iShares JPMorgan USD Emerging Markets Bond fund, which invests in bonds of sovereign and quasi-sovereign entities from emerging markets.
  8. Investing Basics

    What is a Settlement Date?

    A settlement date is the day a security trade must be settled.
  9. Investing Basics

    Explaining Financial Assets

    A financial asset is intangible property that represents a claim on ownership of an entity or contractual rights to future payments.
  10. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
RELATED TERMS
  1. Yield To Maturity (YTM)

    The total return anticipated on a bond if the bond is held until ...
  2. Equity

    The value of an asset less the value of all liabilities on that ...
  3. Discount Bond

    A bond that is issued for less than its par (or face) value, ...
  4. Credit Rating

    An assessment of the credit worthiness of a borrower in general ...
  5. Long-Term Debt

    Long-term debt consists of loans and financial obligations lasting ...
  6. Accelerated Return Note (ARN)

    A short- to medium-term debt instrument that offers a potentially ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the relationship between the current yield and risk?

    The general relationship between current yield and risk is that they increase in correlation to one another. A higher current ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!